U.S. FDA Approves Subcutaneous Administration of Takeda ’s Entyvio (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

OSAKA, Japan April 19, 2024 and CAMBRIDGE, Massachusetts, April 18, 2024– Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved Entyvio® (vedolizumab) subcutaneous (SC) administration for...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news